Clinical Trial Update: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ALTB-268 for efficacy and safety in moderately to severely active ulcerative colitis patients refractory to biologics is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• ALTB-268

Snippet

Sponsor: AltruBio Inc. | Conditions: Ulcerative Colitis | Phase 2 | Status: ACTIVE_NOT_RECRUITING